LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (drug combination treatments). Dataset 1 of 2: Cell count and normalized growth rate inhibition values. - Dataset (ID:20259)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol 1 Concentration | Small Mol 1 Conc Unit | Small Molecule 2 | Small Mol 2 Concentration | Small Mol 2 Conc Unit | Biological Replicate | Technical Replicate | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | Dactolisib | 0.0017 | uM | Neratinib | 0.3704 | uM | 2 | 2 | 1843 | 3836 | 5278 | 0.6206 |
| BT-20 | Dactolisib | 0.0017 | uM | Selumetinib | 10 | uM | 2 | 2 | 1843 | 3770 | 5278 | 0.6022 |
| BT-20 | Alpelisib | 3.3333 | uM | NVP-TAE684 | 1.1111 | uM | 2 | 2 | 1843 | 869 | 5278 | -0.3909 |
| BT-20 | Alpelisib | 0.2138 | uM | Selumetinib | 10 | uM | 2 | 2 | 1843 | 2781 | 5278 | 0.3111 |
| BT-20 | Alpelisib | 1.1111 | uM | Lapatinib | 10 | uM | 2 | 2 | 1843 | 1357 | 5278 | -0.1829 |